hypertension management
DESCRIPTION
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.TRANSCRIPT
![Page 1: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/1.jpg)
Paradigm Shifts in Paradigm Shifts in Hypertension ManagementHypertension Management
Dr. Sachin Verma MD, FICM, FCCS, ICFC
Fellowship in Intensive Care Medicine
Infection Control Fellows Course
Consultant Internal Medicine and Critical Care
Web:- http://www.medicinedoctorinchandigarh.com
Mob:- +91-7508677495
![Page 2: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/2.jpg)
V052004V052004
Paradigm Shifts in Paradigm Shifts in Hypertension ManagementHypertension Management
1.1. Hypertension is an important global problem; Hypertension is an important global problem; Controlling it is challenging; All have room for Controlling it is challenging; All have room for improvement improvement
2.2. Focus on BP goal attainment– sooner rather than Focus on BP goal attainment– sooner rather than laterlater
3.3. Resort to combination therapy readilyResort to combination therapy readily
4.4. Prevent or reduce target organ damagePrevent or reduce target organ damage
![Page 3: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/3.jpg)
![Page 4: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/4.jpg)
Global Burden of HypertensionGlobal Burden of Hypertension2025 Projection2025 Projection
• 26.4% of world adult population had hypertension
• Total of 972 million adults
• Highest prevalence is in
established market economies (eg, North America, Europe)
• 29.2% of world adult population will have hypertension
• Total of 1.56 billion adults
(60% overall; 24% in
developed nations, 80% in developing nations)
• Highest prevalence will be in
economically developing continents (eg, Asia, Africa) – will account for 75% of world’s
hypertensive patients
Year 2000 Year 2025
Kearney PM et al. Lancet. 2005;365:217-223.
![Page 5: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/5.jpg)
![Page 6: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/6.jpg)
35%-40%
20%-25%
>50%
Average reduction in events
(%)
–60
–50
–40
–30
–20
–10
0Stroke
Myocardialinfarction Heart failure
Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;355:1955-1964.
Long-Term Antihypertensive Therapy Significantly Reduces CV Events
![Page 7: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/7.jpg)
Consensus Target BP Levels Since JNC 7 in the Prevention and Management of
Ischemic Heart DiseaseAmerican Heart Association (AHA) Scientific Statement
Area of Concern BP Target (mmHg)
General CAD prevention <140/90
High CAD risk* <130/80
Stable Angina <130/80
Unstable Angina/NSTEMI <130/80
STEMI <130/80
LV Dysfunction <120/80
*High CAD risk = diabetes mellitus, chronic kidney disease, known CAD, CAD equivalent (carotid artery disease, peripheral artery disease, abdominal aortic aneurysm), or 10-year Framingham risk score >10%
Rosendorff et al, Circulation,2007;115: 2761-2788
![Page 8: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/8.jpg)
V052004V052004
Inadequate Control of HypertensionInadequate Control of Hypertension• New England VA Study New England VA Study
– 800 men; mean age, 66 years, many with comorbid conditions800 men; mean age, 66 years, many with comorbid conditions
– Mean duration of HTN = 12.6 years Mean duration of HTN = 12.6 years
– Index visit BP: 146/84 mmHgIndex visit BP: 146/84 mmHg
– Mean of 6.4 hypertension-related visits per yearMean of 6.4 hypertension-related visits per year
• Followed for two 2 yearsFollowed for two 2 years
25% reached goal BP 25% reached goal BP 140/140/90 mm Hg90 mm Hg
– 40% had BP 40% had BP 160/160/90 mm Hg90 mm Hg
• Percentage of visits where therapy was increased:Percentage of visits where therapy was increased:
– 11.2% overall 11.2% overall
– 22%, if DBP 22%, if DBP 90 mm Hg and SBP 90 mm Hg and SBP 165 mm Hg165 mm Hg
– 35% of time when DBP 35% of time when DBP >> 90 mmHg 90 mmHg
Berlowitz et al. N Engl J Med. 1998;339:1957-1963.
![Page 9: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/9.jpg)
V052004V052004
• In 75% of visits documenting elevated blood pressure, In 75% of visits documenting elevated blood pressure, physicians failed to increase the dose of physicians failed to increase the dose of antihypertensive medications or to try new treatments.antihypertensive medications or to try new treatments.
• But clinicians But clinicians did not ignore patients with elevated did not ignore patients with elevated blood pressure.blood pressure. Follow-up visits occurred 2-3 weeks Follow-up visits occurred 2-3 weeks sooner for patients with poorly controlled sooner for patients with poorly controlled hypertension.hypertension.
• Thus, although physicians closely monitored elevated Thus, although physicians closely monitored elevated blood pressure, they repeatedly delayed making blood pressure, they repeatedly delayed making changes to a patient’s regimen. changes to a patient’s regimen.
Inadequate Control of HypertensionInadequate Control of HypertensionClinical InertiaClinical Inertia
Berlowitz et al. N Engl J Med. 1998;339:1957-1963.
![Page 10: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/10.jpg)
Therapeutic (Clinical) Inertia?Therapeutic (Clinical) Inertia?
Satisfaction with current BP levelSatisfaction with current BP level
Elevated SBP more acceptableElevated SBP more acceptable
Use of “soft” reasons to avoid Use of “soft” reasons to avoid intensifying therapyintensifying therapy
Time constraints (15 min visits)Time constraints (15 min visits)
Reluctance to use Reluctance to use combination therapiescombination therapies
Competing prioritiesCompeting priorities
The failure of health care providers to initiate or intensify
therapy when indicated
Causes:
Phillips LS et al. Ann Intern Med. 2001;135:825–834.
![Page 11: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/11.jpg)
“The trial gives new insights into the clinical importance of the rate of achieving BP control:
BP goals need to be reached within a relatively short time (weeks rather than months), at least in patients with hypertension who are at high cardiovascular risk.”
-VALUE Trial, 2004Julius S, et al. Lancet. 2004;363(9426):2022-2031.Julius S, et al. Lancet. 2004;363(9426):2022-2031.
Value: Early Onset of BP Effect
![Page 12: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/12.jpg)
![Page 13: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/13.jpg)
V112004V112004
BP Goal Attainment: JNC VII BP Goal Attainment: JNC VII Expert Roundtable ConclusionsExpert Roundtable Conclusions
“In addition to prescribing the right agent from the start, based on the individual needs of the patient, physicians need to be
more aggressive in bringing their patients to goal”-Michael A. Weber, MD; Founder & Past President of The
American Society of Hypertension
“We want them to attain BP goals while making sure they are adhering to the therapy. The problem is that physicians stop
evaluating the patient’s progress toward the targeted BP level”-Jan N. Basile, MD; Review Committee, JNC 7
Adapted from Weber et al., J Clin Hypertens 2004;6:699–705).
![Page 14: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/14.jpg)
V052004V052004
The Practical Reality of Combination TherapyThe Practical Reality of Combination Therapy
Adding another drug provides greater blood Adding another drug provides greater blood pressure reduction than can be achieved by pressure reduction than can be achieved by titrating the current drug to a higher dosetitrating the current drug to a higher dose
![Page 15: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/15.jpg)
Olmesartanmedoxomil dose
(mg/day)
Reduction in SeSBP(mmHg)
HCTZ dose (mg/day)
Olmesartan Medoxomil/HCTZReduction in SeSBP
4020
100
012.525
30
20
15
10
5
0
2523.0
27.126.8
20.620.1
17.4
9.6
3.3
10.7
15.5
16.0
17.1
HCTZ = hydrochlorothiazide; SeSBP = seated systolic blood pressureChrysant SG et al. Am J Hypertens 2004; 17(3):252-9.
![Page 16: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/16.jpg)
Need for Combination TherapyNeed for Combination Therapy
Elliott WJ. Curr Hypertens Rep. 2002;4:278–285.
Ch
ang
e in
DB
P (
mm
Hg
)
-30
-25
-20
-15
-10
-5
0
0 0.5 1 1.5 2 2.5 3 3.5 4
HOPEProgress
STOP II-β
Syst-ChinaPROGRESS-Combo
TOMHS
Syst-EUR
NORDIL
SHEP
INSIGHT
HOT <90
STOP-βABCD
IDNTEWPHE
RENAAL
HOT <85
HOT <80
UKPDS
VA II
VA I
Number of Antihypertensive Agents
![Page 17: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/17.jpg)
![Page 18: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/18.jpg)
Lifestyle Modifications
![Page 19: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/19.jpg)
Dietary modifications and exercise
Low calorie diets have modest effect on BP in overweight individuals (avg. 5-6 mm Hg).
Aerobic exercise (brisk walking, jogging, or cycling) for 30-60 min., 3-5 times/week, had small effect on BP (2-3 mm Hg).
Relaxation therapies
These activities (stress management, meditation, cognitive therapy, muscle relaxation) reduce by average of 3-4 mm Hg.
![Page 20: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/20.jpg)
Limit alcohol consumption
Excessive alcohol consumption is associated with raised blood pressure, poorer CV and hepatic health.Reducing alcohol can lower BP 3-4 mm Hg.
Limiting excessive consumption of coffee/caffeine
Limit dietary sodium intake< 6 g/day, modest reduction of 2-3 mm Hg.
Encourage smoking cessation
![Page 21: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/21.jpg)
![Page 22: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/22.jpg)
Initiating Treatment
![Page 23: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/23.jpg)
Offer antihypertensive drug treatment to people aged under 80 years with Stage 1 hypertension who have one or more of the following:
Target organ damage
Established cardiovascular disease
Renal disease
Diabetes
10-year CV risk equivalent to 20% or greater.
Offer antihypertensive drug treatment to people of any age with stage 2 hypertension.
![Page 24: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/24.jpg)
For people aged under 40 years with stage 1 hypertension and no evidence of target organ damage, CV disease, renal disease or diabetes
Consider specialist evaluation of secondary causes of hypertension and more detailed assessment of potential target organ damage.
![Page 25: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/25.jpg)
![Page 26: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/26.jpg)
Young subjects (<55 yr) Older subjects (>55 yr)
Step IA or B (if associated sympathetic hyperactivity)
A and/or C
Step 2 Add C or D or both Add D
Step 3 A or B, C and/or D, add EA and C, and/or D, add B or E
The ABCDE algorithm
![Page 27: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/27.jpg)
What is New in Indian Guidelines on
Hypertension - 2013
![Page 28: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/28.jpg)
Due to health related toxic effects
of mercury, mercury
sphygmomanometers
are being replaced by aneroid and
digital sphygmomanometers.
![Page 29: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/29.jpg)
Use of beta-blockers as first line agents in hypertension has receded and these are now recommended as agents for use only in younghypertensives with specific indications.
For routine patients these are no longer recommended as first lineagents
![Page 30: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/30.jpg)
Diuretics are now considered at par with of ACEI’s or ARB’s and calcium channel blockers and not as preferred agents as in previous guidelines.
Chlorthalidone is now available and shown to be better than Hydrochlorothiazide and its usage is tobe preferred.
![Page 31: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/31.jpg)
When blood pressure is high by more than 20/10 mm of Hg systolic and diastolic it is now recommended to start with a combination of drugs.
Monotherapy is not going to be effective in achieving target bloodpressure.
![Page 32: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/32.jpg)
Certain combinations have been shown to be betterthan others in recent trials.
Specially ACEI’s/ARB’s incombination with CCB’s forms a good combination.
![Page 33: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/33.jpg)
J shaped curve exist specially for non revascularised coronary artery disease patients and caution has been advocated in trying to lower blood pressure to low target levels specially in these patients.
![Page 34: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/34.jpg)
A new form of non pharmacological, interventional sympathetic denervation therapy has become recently available and is being evaluated.
![Page 35: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/35.jpg)
JNC-8:
What Might Be Expected
![Page 36: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/36.jpg)
Either a thiazide-type diuretic, CCB,ACEI/ARB will be recommended as initialdrug therapy for most patients.
Direct renin inhibitors will be recommended as an additive
• Chlorthalidone or indapamide should behighlighted as the evidence-based thiazide type diuretic of choice
![Page 37: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/37.jpg)
Summary
![Page 38: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/38.jpg)
It makes less difference which antihypertensive agent is used, unless the patient has a compelling
indication for a specific antihypertensive class
It matters more that BP is appropriately reduced to the chosen BP goal.
![Page 39: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/39.jpg)
The current recommended BP goals in
those with Diabetes and CKD from the
ADA, NKF, and JNC 7 is
<130/80 mm Hg.
![Page 40: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/40.jpg)
The initial drug chosen will be broadened to include
Thiazide-diuretic, ACEI/ARB, or CCB and may include non-atenolol BB’s.
![Page 41: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/41.jpg)
Most patients will require 2 or more antihypertensive agents to get BPeffectively controlled which may bebest approached with initial combinationtherapy, either as a fixed-dose combination (FDC) or as 2 individual initial agents
![Page 42: Hypertension management](https://reader035.vdocuments.mx/reader035/viewer/2022062303/55502165b4c90535638b5536/html5/thumbnails/42.jpg)